顽固性高血压患者的肾交感神经去神经支配：一项可行性研究。
Renal Sympathetic Denervation in Patients with Resistant Hypertension: A Feasibility Study.
作者信息
Kario Kazuomi, Rumoroso Jose Ramon, Okawara Yukie, Pérez de Prado Armando, Garcia Fernandez Eulogio, Kagitani Hideaki, Goicolea Gómez Francisco Javier, Rodríguez Leor Oriol, Stankovic Goran
机构信息
Department of Cardiovascular Medicine, Jichi Medical University School of Medicine, Tochigi, Japan.
Interventional Cardiology Department, Hospital Galdakao, Bilbao, Spain.
出版信息
Pulse (Basel). 2019 Apr;6(3-4):137-143. doi: 10.1159/000490620. Epub 2018 Jul 25.
BACKGROUND/AIMS: We assessed the feasibility of renal sympathetic denervation (RDN) treatment in patients with resistant hypertension using the Iberis® RDN system. This study was a prospective, multicenter, single-arm feasibility registry.
METHODS
We collected data from patients who underwent RDN treatment using the Iberis system. From November 2014 to February 2016, 16 patients from 6 centers in Europe were enrolled in this registry.
RESULTS
Consistent reductions in the 24-h systolic blood pressure (SBP) and diastolic blood pressure were obtained. At any follow-up point, more than 70% of the patients were responders. The change in the 24-h SBP at 1 month was strongly correlated with that at 12 months.
CONCLUSION
The Iberis system is safe and effective in patients for the treatment of resistant hypertension. Furthermore, our results suggest that we can estimate the effect of RDN in the long term at the 1-month follow-up point using the 24-h SBP.
背景/目的：我们使用Iberis®肾交感神经消融（RDN）系统评估了RDN治疗顽固性高血压患者的可行性。本研究是一项前瞻性、多中心、单臂可行性登记研究。
方法
我们收集了使用Iberis系统接受RDN治疗患者的数据。2014年11月至2016年2月，来自欧洲6个中心的16例患者纳入该登记研究。
结果
24小时收缩压（SBP）和舒张压持续降低。在任何随访点，超过70%的患者为反应者。1个月时24小时SBP的变化与12个月时的变化密切相关。
结论
Iberis系统治疗顽固性高血压患者安全有效。此外，我们的结果表明，我们可以在1个月随访点使用24小时SBP评估RDN的长期效果。
Zotero 插件